GVK teams up with Endo on early-stage pain drug

Indian CRO GVK Biosciences has pulled in another pharma partner, teaming with Endo Pharmaceuticals ($ENDP) to discover novel small molecules targeting pain and inflammation.

The deal comes out of GVK's Early Discovery Assets portfolio, a system through which the CRO develops discovery targets internally and then, once they've reached a stage of demonstrated value, looks to partner and co-develop them with biotechs and pharmas.

The Endo partnership is focused on a small-molecule therapy targeting "an exciting protein," GVK said, and the deal is an early step in demonstrating the value of the company's EDA offerings, CEO Manni Kantipudi said in a statement.

For Endo, the allure of GVK went beyond just its novel approach to partnering, said Sandeep Gupta, Endo's senior vice president of drug discovery and early development. "With their world-class infrastructure and an experienced scientific team, I have no doubt that they will execute on the program goals and add to our portfolio of development candidates that provide novel treatment options for the patients," Gupta said in a statement.

Earlier this month, GVK snagged another pharma team-up with another innovative partnering structure: The CRO is working with Onconova Therapeutics on early-stage cancer therapies, but the deal increases GVK's financial stake as it meets certain milestones, getting as high as 50-50 by the time a candidate becomes an IND.

- read the announcement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.